Edward Rosen is the founder and managing partner of Glendevon Life Sciences. He is a serial entrepreneur with a foundation of success in multinational drug, device and diagnostic companies and extensive experience out-licensing technology from academic institutions. Ed is currently an Executive-in-Residence for the Technology Ventures Group at Columbia University and was the founding CEO, President, Chief Executive Officer and a Director of Elucida Oncology, Inc. Ed has more than 25 years of operational and leadership experience in the life sciences industry, including Worldwide Vice President of Marketing for a large division of Johnson & Johnson. Ed attended the University of Lincoln in the UK, receiving a BA with honors in Business.
The Glendevon strategy will seek to generate long-term capital appreciation by leveraging an exceptional team to found and make venture capital investments in life science companies – including biotechnology, pharmaceutical, diagnostics and medical devices.
We do this by bridging academic research and Series A investment by:
- Establishing exclusive licensing of early-stage life science intellectual property, prioritizing probability-of-success as an investment philosophy.
- Targeting quality niche opportunities less attractive to larger funds due to scale.
- Defining realizable and affordable milestones to enable strong Series A fundraising potential.
- Supplying high-talent Management Service Team to enhance performance of Portfolio Companies and tailor leadership to early-stage company needs.
Prior team successes include founding/co-founding and/or senior executive and scientific leadership for Lodo Therapeutics, Elucida Oncology, Bioleap, Revolution Medicine, Arcellx, NKarta Therapeutics, Cell Therapy Accelerator, Battersea Biotech, InFocus Capital Partners, Equitable and Alliance Capital Partners, International Fund Administration and Sierra Global Management.